Literature DB >> 6520169

Determination of free 3-methoxy-4-hydroxyphenylglycol with several other monoamine metabolites in plasma by high-performance liquid chromatography with amperometric detection.

A Minegishi, T Ishizaki.   

Abstract

A reversed-phase liquid chromatographic method with amperometric detection has been developed for determining free 3-methoxy-4-hydroxyphenylglycol in plasma. The method is based on a simple and rapid extraction procedure employing a small C18 column. Vanillyl alcohol was used as an internal standard to obtain a good reproducibility. The 3-methoxy-4-hydroxyphenylglycol concentrations measured with the present method were in reasonable agreement with recently published data using high-performance liquid chromatography with amperometric detection and gas chromatography with mass spectrometry. The additional advantage of the present assay is that it can be performed in parallel with the quantification of other monoamine metabolites in plasma.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6520169     DOI: 10.1016/s0378-4347(00)84690-3

Source DB:  PubMed          Journal:  J Chromatogr


  8 in total

1.  Raised plasma concentrations of 3-methoxy-4-hydroxyphenylethyleneglycol in cirrhotic patients with or without hepatic encephalopathy.

Authors:  H Echizen; A Minegishi; S Hayashi; N Umeda; T Oda; T Ishizaki
Journal:  Gut       Date:  1989-05       Impact factor: 23.059

2.  Clomipramine-induced serum prolactin as a marker for serotonin and dopamine turnover: results of an open label study.

Authors:  Joachim Cordes; Kai G Kahl; Christian Werner; Uwe Henning; Gunnar Regenbrecht; Rolf Larisch; Christian Schmidt-Kraepelin; Johanna Thünker; Marcus W Agelink; Stefan Löffler; Thomas Hohlfeld; Wolfgang Gaebel; Ansgar Klimke
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-03-15       Impact factor: 5.270

3.  Comparison of lithium, aripiprazole and olanzapine as augmentation to paroxetine for inpatients with major depressive disorder.

Authors:  Reiji Yoshimura; Hikaru Hori; Wakako Umene-Nakano; Atsuko Ikenouchi-Sugita; Asuka Katsuki; Kiyokazu Atake; Jun Nakamura
Journal:  Ther Adv Psychopharmacol       Date:  2014-06

4.  Neuropsychological measures of attention and memory function in schizophrenia: relationships with symptom dimensions and serum monoamine activity.

Authors:  Robert D Oades; Bernd Röpcke; Uwe Henning; Ansgard Klimke
Journal:  Behav Brain Funct       Date:  2005-08-09       Impact factor: 3.759

5.  COMT Val158Met, but not BDNF Val66Met, is associated with white matter abnormalities of the temporal lobe in patients with first-episode, treatment-naïve major depressive disorder: a diffusion tensor imaging study.

Authors:  Kenji Hayashi; Reiji Yoshimura; Shingo Kakeda; Taro Kishi; Osamu Abe; Wakako Umene-Nakano; Asuka Katsuki; Hikaru Hori; Atsuko Ikenouchi-Sugita; Keita Watanabe; Satoru Ide; Issei Ueda; Junji Moriya; Nakao Iwata; Yukunori Korogi; Marek Kubicki; Jun Nakamura
Journal:  Neuropsychiatr Dis Treat       Date:  2014-06-25       Impact factor: 2.570

6.  Catechol-O-methyltransferase Val158Met genotype and the clinical responses to duloxetine treatment or plasma levels of 3-methoxy-4-hydroxyphenylglycol and homovanillic acid in Japanese patients with major depressive disorder.

Authors:  Kiyokazu Atake; Reiji Yoshimura; Hikaru Hori; Asuka Katsuki; Jun Nakamura
Journal:  Neuropsychiatr Dis Treat       Date:  2015-04-03       Impact factor: 2.570

7.  Antidopaminergic medication in healthy subjects provokes subjective and objective mental impairments tightly correlated with perturbation of biogenic monoamine metabolism and prolactin secretion.

Authors:  Tanja Veselinović; Ingo Vernaleken; Paul Cumming; Uwe Henning; Lina Winkler; Peter Kaleta; Michael Paulzen; Christian Luckhaus; Gerhard Gründer
Journal:  Neuropsychiatr Dis Treat       Date:  2018-04-27       Impact factor: 2.570

8.  Plasma levels of IL-6 in patients with untreated major depressive disorder: comparison with catecholamine metabolites.

Authors:  Reiji Yoshimura; Taro Kishi; Nakao Iwata
Journal:  Neuropsychiatr Dis Treat       Date:  2019-09-13       Impact factor: 2.570

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.